Literature DB >> 11431713

Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases.

B Delahunt1, J N Eble, M R McCredie, P B Bethwaite, J H Stewart, A M Bilous.   

Abstract

Whereas papillary renal cell carcinoma is now established as a subtype of renal cell neoplasia, division of these tumors into 2 distinctive morphotypes has been proposed. Type 1 tumors have cells with scanty pale cytoplasm arranged in a single layer on the basement membrane of papillary cores. In these tumors, psammoma bodies and foamy macrophages are frequently seen, and the tumors frequently express cytokeratin 7. Type 2 tumor cells have pseudostratified nuclei and usually have voluminous eosinophilic cytoplasm. Recent studies have supported this subclassification of papillary renal cell carcinoma by demonstrating differing genotypes for type 1 and 2 tumors. To further study the subclassification of papillary renal carcinoma, we compared clinical features, nuclear grade, stage, tumor growth kinetics, and survival in a series of 50 type 1 and 16 type 2 papillary renal cell carcinomas. Comparison of patient age at presentation, sex, and primary tumor size shows no significant difference between the 2 tumor types. Type 1 tumors were of significantly lower Fuhrman grade (P =.0001) and higher Robson stage (P =.009) than type 2 tumors. There was no significant difference when tumors were staged according to the TNM classification. Assessment of tumor growth kinetics showed significantly different mean silver-staining nucleolar organizer region (AgNOR) scores and Ki-67 indices (AgNOR type 1, 3.83, type 2, 7.24, P =.0001; Ki-67 type 1, 3.17%, type 2, 6.01%, P =.0002). Multivariate analysis showed tumor type (P =.03), presence of metastases (P =.04), AgNOR score (P =.001), and Ki-67 index (P =.03) to be independently associated with survival. These results provide evidence of the clinical utility of dividing papillary renal cell carcinomas into 2 types according to histologic characteristics. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431713     DOI: 10.1053/hupa.2001.24984

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  75 in total

1.  Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis.

Authors:  T Urge; O Hes; J Ferda; Z Chudácek; V Eret; M Michal; M Brunelli; G Martignoni; M Hora
Journal:  World J Urol       Date:  2010-05-08       Impact factor: 4.226

Review 2.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

Review 4.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Authors:  Simon Chowdhury; Marc R Matrana; Christopher Tsang; Bradley Atkinson; Toni K Choueiri; Nizar M Tannir
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

Review 5.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

6.  Distribution of Vascular Patterns in Different Subtypes of Renal Cell Carcinoma. A Morphometric Study in Two Distinct Types of Blood Vessels.

Authors:  Amparo Ruiz-Saurí; V García-Bustos; E Granero; S Cuesta; M A Sales; V Marcos; A Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2017-07-01       Impact factor: 3.201

Review 7.  Characterizing Indeterminate Renal Masses with Molecular Imaging: the Role of 99mTc-MIBI SPECT/CT.

Authors:  Andrew M Reynolds; Kristin Kelly Porter
Journal:  Curr Urol Rep       Date:  2017-09-12       Impact factor: 3.092

8.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

9.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Authors:  Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 10.  Recent developments in the treatment of renal cell carcinoma.

Authors:  Janice P Dutcher
Journal:  Ther Adv Urol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.